ATE519496T1 - Therapeutische anwendung von g-csf - Google Patents

Therapeutische anwendung von g-csf

Info

Publication number
ATE519496T1
ATE519496T1 AT03712209T AT03712209T ATE519496T1 AT E519496 T1 ATE519496 T1 AT E519496T1 AT 03712209 T AT03712209 T AT 03712209T AT 03712209 T AT03712209 T AT 03712209T AT E519496 T1 ATE519496 T1 AT E519496T1
Authority
AT
Austria
Prior art keywords
group
csf
rats
days
test
Prior art date
Application number
AT03712209T
Other languages
English (en)
Inventor
Didier Pourquier
Didier Moukoko
Original Assignee
Didier Pourquier
Didier Moukoko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Didier Pourquier, Didier Moukoko filed Critical Didier Pourquier
Application granted granted Critical
Publication of ATE519496T1 publication Critical patent/ATE519496T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AT03712209T 2002-01-18 2003-01-06 Therapeutische anwendung von g-csf ATE519496T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0200610A FR2834898B1 (fr) 2002-01-18 2002-01-18 Nouvelle application therapeutique du g-csf, du gm-csf et du scf
PCT/FR2003/000013 WO2003061685A1 (fr) 2002-01-18 2003-01-06 Application therapeutique du g-csf, du gm-csf et du scf

Publications (1)

Publication Number Publication Date
ATE519496T1 true ATE519496T1 (de) 2011-08-15

Family

ID=27589516

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03712209T ATE519496T1 (de) 2002-01-18 2003-01-06 Therapeutische anwendung von g-csf

Country Status (8)

Country Link
EP (2) EP2277529B1 (de)
AT (1) ATE519496T1 (de)
DK (1) DK1465653T3 (de)
ES (2) ES2389244T3 (de)
FR (1) FR2834898B1 (de)
PT (1) PT1465653E (de)
SI (1) SI1465653T1 (de)
WO (1) WO2003061685A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4891477B2 (ja) 1997-10-02 2012-03-07 マックス−プランク−ゲゼルシャフト ツール フォーデルング デル ヴィッセンシャフテン エー.ヴェー. 血管新生及び/または既存細動脈網から側枝動脈及び/または他の動脈の発達の調節に関する方法
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7695723B2 (en) * 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
RU2353385C2 (ru) * 2002-12-31 2009-04-27 Зигнис Байосайенс Гмбх Унд Ко. Кг Способы лечения неврологических состояний с применением гематопоэтических факторов роста
EP2036571A1 (de) 2007-09-13 2009-03-18 Sygnis Bioscience GmbH & Co. KG Verwendung von G-CSF für die Behandlung von Schlaganfall
US8895291B2 (en) 2010-10-08 2014-11-25 Terumo Bct, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
US9617506B2 (en) 2013-11-16 2017-04-11 Terumo Bct, Inc. Expanding cells in a bioreactor
EP3613841B1 (de) 2014-03-25 2022-04-20 Terumo BCT, Inc. Passives ersetzen von medien
CN106715676A (zh) 2014-09-26 2017-05-24 泰尔茂比司特公司 按计划供养
US10039808B2 (en) 2014-10-22 2018-08-07 Michael Chez Method of treating or improving neurological function in a human subject
US9925244B1 (en) 2015-02-17 2018-03-27 Michael Chez Treatment of warts in non-immunosuppressed patients
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11702634B2 (en) 2017-03-31 2023-07-18 Terumo Bct, Inc. Expanding cells in a bioreactor
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4891477B2 (ja) * 1997-10-02 2012-03-07 マックス−プランク−ゲゼルシャフト ツール フォーデルング デル ヴィッセンシャフテン エー.ヴェー. 血管新生及び/または既存細動脈網から側枝動脈及び/または他の動脈の発達の調節に関する方法
DE10033219A1 (de) * 2000-07-07 2002-01-24 Univ Heidelberg Neuroprotektive Wirkung von Granulocyten-Colony Stimmulierendem Faktor (G-CSF)
US20040120925A1 (en) * 2001-03-12 2004-06-24 Masahiro Toda Remedies for nerve damages

Also Published As

Publication number Publication date
FR2834898A1 (fr) 2003-07-25
EP1465653A1 (de) 2004-10-13
FR2834898B1 (fr) 2005-06-10
DK1465653T3 (da) 2011-10-17
ES2370290T3 (es) 2011-12-14
EP2277529B1 (de) 2012-06-06
ES2389244T3 (es) 2012-10-24
EP1465653B1 (de) 2011-08-10
SI1465653T1 (sl) 2011-11-30
EP2277529A1 (de) 2011-01-26
WO2003061685A1 (fr) 2003-07-31
PT1465653E (pt) 2011-10-18

Similar Documents

Publication Publication Date Title
ATE519496T1 (de) Therapeutische anwendung von g-csf
El Gazaerly et al. Effect of transforming growth factor Beta 1 on wound healing in induced diabetic rats
DE69030880T2 (de) Zusammensetzung zur Stimulierung des Immunsystems
EP2548880A3 (de) Zusammensetzungen zur Erhöhung der Telomeraseaktivität
CA2369810A1 (en) Method of treating pain
WO2012065651A1 (en) A synergistic composition of plant extracts for treating skin diseases involving abnormal cell growth
DK0484340T3 (da) Behandling til nedsættelse af ødem ved hjerne- og muskelbeskadigelser
US6174541B1 (en) Skin aging and wound treatment using cell migration agents
CA2045605A1 (en) Treatment of leukocyte dysfunction with gm-csf
EP1621207B1 (de) Kombination von Defibrotide und G-CSF und ihre Verwendung zur Aktivierung hämatopoietischer Vorläuferzellen
CA2563800A1 (en) Spinosyns for wound healing
Silver et al. Interleukin 1β improves survival following cecal ligation and puncture
CA2332935A1 (en) A method for inducing production of growth factors
Austin et al. The beneficial effects of immunostimulation in posttraumatic sepsis
DE69623316D1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
Lim et al. Changes in cytokine signaling and extracellular matrix production induced by inflammatory factors in cultured vocal fold fibroblasts
Haan et al. Microenvironmentally dependent effects on murine haemopoiesis by a prolonged interleukin‐1 treatment
Zucali et al. Hematopoietic effects of interleukin-1
Coerper et al. Ulcus cruris venosum: Chirurgisches Debridement, antibiotische Therapie und Stimulation mit thrombozytären Wachstumsfaktoren
CN1589904A (zh) 造血干细胞动员剂制备治疗糖尿病药物的用途
Boxill et al. Epinephrine prepotency over pressoreceptor responses elicited by elevated blood pressure
Kh CHANGES IN CYTOKINE PROFILE AFTER SURGERY
RU2068266C1 (ru) Способ повышения остроты слуха
Mozaffari et al. In vitro Comparison of Viability of Human Gingival Fibroblast Cells on Collagen Barriers
RU2587638C1 (ru) Способ оптимизации лечения глубоких ожогов

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1465653

Country of ref document: EP